CLK3: A Drug Target / Disease Biomarker (G1198)

Target Name: CLK3

NCBI ID: G1198

CLK3

CLK3: A Drug Target / Disease Biomarker

CLK3, short for clock gene 3, is a gene that has been identified as a potential drug target for the treatment of various neurological disorders. The CLK3 gene is a non-coding RNA molecule that is responsible for regulating the activity of several clock genes, which are responsible for controlling the circadian rhythms that regulate various physiological processes in the body.

Studies have shown that CLK3 is involved in the development and progression of several neurological disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These disorders are characterized by the progressive loss of brain cells and the development of characteristic symptoms that affect cognitive and motor function.

One of the main reasons for the involvement of CLK3 in these disorders is its role in the regulation of the circadian rhythms. The circadian rhythms are responsible for controlling various physiological processes that are essential for life, including sleep, eating, and movement. CLK3 is responsible for regulating the activity of the clock genes that produce the proteins that are involved in the circadian rhythms.

Studies have shown that the activity of the CLK3 gene is regulated by a variety of factors, including the levels of certain chemicals called nutrients, such as vitamin D and melatonin. These nutrients are essential for the proper functioning of the clock genes, and the levels of them can affect the activity of the CLK3 gene.

Another factor that has been shown to be involved in the regulation of the CLK3 gene is the presence of certain proteins, called kinases. Kinases are a type of enzyme that can regulate the activity of other proteins, and they are involved in the regulation of many different genes, including the CLK3 gene.

Research has also shown that the CLK3 gene is involved in the development and progression of several other neurological disorders, including epilepsy and schizophrenia. These disorders are characterized by the progressive loss of brain cells and the development of characteristic symptoms that affect cognitive and motor function.

In addition to its involvement in the regulation of the circadian rhythms and its involvement in the development and progression of neurological disorders, CLK3 is also thought to be involved in the regulation of other physiological processes in the body. For example, studies have shown that the CLK3 gene is involved in the regulation of the production of hormones that regulate various physiological processes, such as blood pressure and body weight.

Overall, CLK3 is a gene that has been identified as a potential drug target for the treatment of various neurological disorders. The CLK3 gene is involved in the regulation of the circadian rhythms and its activity is regulated by a variety of factors, including the levels of certain nutrients and the presence of certain proteins. Further research is needed to fully understand the role of the CLK3 gene in the development and treatment of neurological disorders.

Protein Name: CDC Like Kinase 3

Functions: Dual specificity kinase acting on both serine/threonine and tyrosine-containing substrates. Phosphorylates serine- and arginine-rich (SR) proteins of the spliceosomal complex. May be a constituent of a network of regulatory mechanisms that enable SR proteins to control RNA splicing and can cause redistribution of SR proteins from speckles to a diffuse nucleoplasmic distribution. Phosphorylates SRSF1 and SRSF3. Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells

The "CLK3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLK3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets